The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia

Leukemia Research

Volumn 35, Issue 7, 2011, Pages 879-884

  Liu, Yanhui ^a   Wang, Zhaoyue ^a   Jiang, Miao ^a   Dai, Lan ^a   Zhang, Wei ^a   Wu, Depei ^a   Ruan, Changgeng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Annexin II; Arsenic trioxide; Fibrinolysis

Indexed keywords

ARSENIC TRIOXIDE; DAUNORUBICIN; LIPOCORTIN 2; PLASMIN; RETINOIC ACID; SMALL INTERFERING RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPERFIBRINOLYSIS; MALE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS;

ADOLESCENT; ADULT; AGED; ANNEXIN A2; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; BLOOD COAGULATION TESTS; BLOTTING, WESTERN; CELL PROLIFERATION; FEMALE; FIBRINOLYSIN; FIBRINOLYSIS; FLOW CYTOMETRY; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OXIDES; PLASMINOGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TISSUE PLASMINOGEN ACTIVATOR; TRETINOIN; YOUNG ADULT;

EID: 79958720444     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.11.008     Document Type: Article

References (37)

1. Degos L. The history of acute promyelocytic leukemia. Br J Haematol 2003, 122:539-553.
2. Ohno R., Asou N., Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 2003, 17:1454-1463.
3. Barbui T., Falanga A. Disseminated intravascular coagulation in acute leukemia. Semin Thromb Hemost 2001, 27. 27-12.
4. Aoki N. Hemostasis associated with abnormalities of fibrinolysis. Blood Rev 1989, 3:11-17.
5. Imaoka S., Ueda T., Shibata H., et al. Fibrinolysis in patients with acute promyelocytic leukemia and disseminated intravascular coagulation during heparin therapy. Cancer 1986, 58:1736-1738.
6. Hajjar K.A., Krishnan S. Annexin II: a mediator of the plasmin/plasminogen activator system. Trends Cardiovasc Med 1999, 9:128-138.
7. Menell J.S., Cesarman G.M., Jacovina A.T., et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999, 340:994-1004.
8. Olwill S.A., McGlynn H., Gilmore W.S., et al. Annexin II cell surface and mRNA expression in human acute myeloid leukaemia cell lines. Thromb Res 2005, 115:109-114.
9. Nasr R., Lallemand-Breitenbach V., Zhu J., et al. Therapy-induced PML/RARα proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res 2009, 15:6321-6326.
10. Barbui T., Finazzi G., Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998, 91:3093-3102.
11. Zhao W., Wang X., Guo W., et al. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment. Chin Med J 2000, 113:236-240.
12. Degos L., Dombret H., Chomienne C., et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995, 5:2643-2653.
13. Falanga A., Evangelista V., Belotti D., et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 1995, 86:1072-1081.
14. Guo W., Zhu J., Wang H. Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells. Zhonghua Xue Ye Xue Za Zhi 1999, 20:453-455.
15. Zhang X., Zhou H., Wang J., et al. Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator. Thromb Res 2002, 106:63-70.
16. Olwill S.A., McGlynn H., Gilmore W.S., et al. All-trans retinoic acid-induced downregulation of annexin II expression in myeloid leukaemia cell lines is not confined to acute promyelocytic leukaemia. Br J Haematol 2005, 131:258-264.
17. Xie Y., Wang Z.Y., Zhang W., et al. The fibrinolytic activity in leukemic cell lines and its alteration on all-trans retinoic acid treatment. Zhonghua Xue Ye Xue Za Zhi 2006, 27:588-592.
18. Zhang X.H., Hu Y., Bao L., et al. Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia. Chin Med J 2009, 122:1969-1973.
19. 19, Tallman M.S., Abutalib S.A., Altman J.K. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia. Semin Thromb Hemost 2007, 33:330-338.
20. Kassam G., Choi K.S., Ghuman J., et al. The role of annexin II tetramer in the activation of plasminogen. J Biol Chem 1998, 273:4790-4799.
21. Law A.L., Ling Q., Hajjar K.A., et al. Annexin A2 regulates phagocytosis of photoreceptor outer segments in the mouse retina. Mol Biol Cell 2009, 20:3896-3904.
22. Hajjar K.A., Jacovina A.T., Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator I. Identity with annexin II. J Biol Chem 1994, 269:21191-21197.
23. Zhu C., Fabien G., Philippe R., et al. PLZF-RARα fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Nati Acad Sci USA 1994, 91:1178-1182.
24. Medvedeva N.A., Cherepanova V.V., Tarasova L.N., et al. Hemostatic changes during the treatment of acute promyelocytic leukemia with all-transretinoic acid. Ter Arkh 2000, 72:27-31.
25. Tallman M.S., Lefebvre P., Baine R.M., et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004, 2:1341-1350.
26. Dombret H., Scrobohaci M.L., Ghorra P., et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia 1993, 7:2-9.
27. Bulens F., Nelles L., Van den Panhuyzen N., et al. Stimulation by retinoids of tissue-type plasminogen activator secretion in cultured human endothelial cells: relations of structure to effect. J Cardiovasc Pharmacol 1992, 19:508-514.
28. Stefano V.De, Teofili L., Sica S., et al. Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia. Blood 1995, 86:3535-3541.
29. Kwaan H.C., Wang J., Boggio L.N. Abnormalities in hemostasis in acute promyelocytic leukemia. Hematol Oncol 2002, 20:33-41.
30. Stein E., McMahon B., Kwaan H., et al. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 2009, 22:153-163.
31. Falanga A., Barbui T. Coagulopathy of acute promyelocytic leukemia. Acta Haematol 2001, 106:43-51.
32. Robbie L., Berry S., Moir E., et al. Myeloid leukaemic cells can lyse fibrin directly. Br J Haematol 2000, 111:524-529.
33. Wada H., Kumeda Y., Ogasawara Z., et al. Plasminogen activators and their inhibitors in leukemic cell homogenates. Am J Haematol 1993, 42:166-170.
34. López-Pedrera C., Jardí M., del Mar Malagón M., et al. Tissue factor (TF) and urokinase plasminogen activator receptor (uPAR) and bleeding complications in leukemic patients. Thromb Haemost 1997, 77:62-70.
35. Egbring R., Schmidt W., Fuchs G., et al. Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood 1977, 49:219-231.
36. Wassenaar T., Black J., Kahl B., et al. Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. Hematol Oncol 2008, 26:241-246.
37. Meijers J.C., Oudijk E.J., Mosnier L.O., et al. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000, 108:518-523.